The clinical catalyst (FDA alignment on Phase 3 design and strong efficacy data) dominates the EPS miss. Watch for EULAR 2026 presentations (June) and Phase 3 trial initiation in H2 2026. The cash runway into Q2 2027 provides a sufficient buffer for the registrational trial. Any safety or efficacy readout from the broader autoimmune dataset could further re-rate the stock.
Price Chart
Executive Summary
Artiva reported Q1 2026 GAAP EPS of -$0.95, missing the Street consensus of -$0.84 by 13.1%, while revenue remained $0. The net loss widened to $23.5M from $20.3M a year ago. However, the stock is likely to move on the positive clinical catalyst: FDA alignment on a single Phase 3 registrational trial for AlloNK in refractory RA, with 71% ACR50 response at six months in initial data, supporting a potential path to market.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.95 vs consensus -$0.84 (13.1% miss)
- Net loss $23.5M vs $20.3M YoY, driven by higher R&D spend ($19.3M vs $17.1M)
- Cash runway into Q2 2027 with $86.8M in cash and investments
- FDA alignment on single Phase 3 registrational trial for AlloNK in refractory RA; trial initiation H2 2026
- 71% ACR50 response at six months in refractory RA patients from Phase 2a basket trial
- No CRS, ICANS, or treatment discontinuations reported; outpatient administration profile
- Multiple abstracts accepted at EULAR 2026, including a late-breaking oral presentation
Financial Impact
EPS miss of $0.11 vs consensus; net loss increased $3.2M YoY; cash burn rate ~$7.8M/month
Risk Factors
- Phase 3 trial may fail to replicate Phase 2a efficacy results
- FDA minutes from alignment meeting could differ from Artiva's interpretation
- Cash burn may require dilutive financing before Q2 2027 if trial costs exceed expectations
- Competition from CAR-T therapies in autoimmune indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290961 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access